NUBEQA 300 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, JEVTANA 60 mg concentrate and solvent for solution for infusion.
DAROTAXEL
Phase 2 small_molecule active
Quick answer
NUBEQA 300 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, JEVTANA 60 mg concentrate and solvent for solution for infusion. for metastatic castration-resistant prostate cancer is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- metastatic castration-resistant prostate cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active